Three Words, One Mission - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/voices/yukse... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025

Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC - Yüksel Ürün @yukselurun.bsky.social @erikahamilton9.bsky.social oncodaily.com/voices/yukse... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025

Global Cancer Burden Calls for Action on Prevention and Equity - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/voices/yukse... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Proud to join such inspiring colleagues as an #ESMOAmbassadors Excited for #ESMO25 and all the new #CancerResearch ahead. @myesmo.bsky.social

@ptarantinomd.bsky.social ; @yukselurun.bsky.social ; @arndtvogel.bsky.social ; @tiansterzhangmd.bsky.social

Hastalarımıza gerçeği anlatmak. Ne korku satmak, ne de sahte umut vermek. Medya, veriyi dürüst anlattığında güç katar. Ama çarpıtılmış grafikler, abartılmış başlıklar, seçilmiş veriler… Korku yaratır. Umudu kirletir. Gerçeği savunmak, hastalarımızı korumaktır. Veri konuşsun, biz dinleyelim.

Cancer care often forgets those at the edges: teens, elders, people with rare cancers. Their needs don’t fit the standard path. Fertility, intimacy, body image deserve the same care as the tumor. @oncoalert.bsky.social @oncoassist.bsky.social

Every patient is first a human being with a name, a story, a dream. Dignity is part of the treatment. Never reduce a life to a diagnosis… @ascocancer.bsky.social @myesmo.bsky.social @oncoalert.bsky.social

Proud of our rising star Coşkun and all colleagues. This meta-analysis on PARP inhibitors and thrombosis risk asks the right question for patients. @oncoalert.bsky.social @myesmo.bsky.social @apccc.bsky.social @drchoueiri.bsky.social @neerajagarwal.bsky.social

“Medice, cura te ipsum” Doctor, heal yourself. Even healers burn out. Rest is not weakness, it is repair. Caring for others starts with caring for yourself. @oncoalert.bsky.social @oncbrothers.bsky.social @ascocancer.bsky.social @myesmo.bsky.social

Dr. Yüksel Ürün’s Highlights from VIRO 2025 on Personalizing Treatment in the Frontline Setting @yukselurun.bsky.social oncodaily.com/pulse/dr-yuk... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #VIRO #VIRO25

Join Us for Global Voices in Renal Oncology Virtual Congress 2025 @yukselurun.bsky.social oncodaily.com/pulse/global... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Global voices, shared hope. Excited to join colleagues at VIRO 2025—working together for patients in renal cancer. #OncoDaily #VIRO2025 @oncodaily.bsky.social docs.google.com/forms/d/e/1F...

🌍 𝗚𝗹𝗼𝗯𝗮𝗹 𝗩𝗼𝗶𝗰𝗲𝘀 𝗶𝗻 𝗥𝗲𝗻𝗮𝗹 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 (𝗩𝗜𝗥𝗢) 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 📅 Sept 11–12, 2025 | 🩺 Chaired by Dr. Rana McKay & co-chaired by Dr. Yüksel Ürün @yukselurun.bsky.social 🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲: forms.gle/qcQyaGMQfHDh... oncodaily.com/pulse/rana-m... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd

Meet the Experts of VIRO 2025 - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/pulse/yuksel... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Liquid Biopsy Is No Longer the Future - Yüksel Ürün @yukselurun.bsky.social @neerajagarwal.bsky.social @euplatinum.bsky.social oncodaily.com/science/liqu... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LiquidBiopsy

Cancer Prevention is the Quiet Revolution - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/voices/yukse... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Every patient teaches me something new about strength, hope, and why we fight.

Science Is Better When It’s Shared - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/blog/science... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Science

Breast Cancer Care Shouldn’t Be a Luxury - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/insight/yuks... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer

This sounds like an exciting step forward! How soon do you think cancer vaccines like these could become more widely used?

A Promising Option for Non–Non-Clear-Cell Renal Cell Carcinoma - Yüksel Ürün @yukselurun.bsky.social @euplatinum.bsky.social oncodaily.com/science/yuks... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #nccRCC #KidneyCancer

How Should We Treat mCRPC and HRR Deficiency? - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/blog/how-sho... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #mCRPC #HRR #ProstateCancer

First Positive Phase 3 Trial for a Bispecific ADC - Paolo Tarantino @ptarantinomd.bsky.social @yukselurun.bsky.social oncodaily.com/insight/paol... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC

Cancer vaccines: the next frontier is now. From HBV & HPV to personalized mRNA shots @oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social

Take care of your kidneys, protect your life. 4 simple actions = less risk, better outcomes: 🚭 Quit smoking ⚖️ Stay at a healthy weight 🏃‍♀️ Be active, avoid trauma 💧 Drink water, skip alcohol Because prevention is power @oncoalert.bsky.social @drchoueiri.bsky.social @kidneycan.bsky.social

🎗 Gerçek bilim bazen zor konuşur. Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız. 📌 Evet, süreç yorucu. 📌 Evet, sonuç her zaman adil değil. Ama geçmişe göre çok daha iyiyiz. Birçok tümörde, yıllar kazandıran tedaviler var artık

Bugünkü kelimemiz: Radikal Prostatektomi 🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek? 👨‍⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır. 🎯 Bilmek güç verir. Takipte kalın, diğer terimleri de birlikte öğrenelim.

🔬 Klinik Araştırma Nedir? Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır. Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar, hem de gelecekte binlerce hayatın değişmesine katkı sağlar. #science

Biyopsi = Şüpheli dokudan parça alıp mikroskopla incelemek. Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.” 🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.

I have two favourite studies from #ASCO25 @christielibrary.bsky.social @mcrcnews.bsky.social 👇🏽 www.nejm.org/doi/full/10....

Our new JAMA Cardiology study finds that many US adults don't know that they have hypertension, diabetes, or high cholesterol Nearly 1 in 3 young adults w/ hypertension, 2 in 5 with diabetes, and 1 in 4 with high cholesterol are unaware of their condition. bit.ly/45an6MC #medsky #cardiosky

#ASMS2025 ThP046 come to check out Jenny’s poster! Don’t miss this great opportunity to meet Jenny! @asms.org @jyates.bsky.social @femalesinms.bsky.social #teammassspec @garcialabms.bsky.social @proteomicsnews.bsky.social

This is so true. We have to continually work together to get better #healthcare delivery & #research advances to ALL #patients.

Every oncologist is a patient advocate. Right treatment. Right time. For every patient. #ASCO25 #Oncology #CancerCare #AccessMatters @oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social

Thrilled to share our new analysis from CheckMate 901! 🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS. ➡️A new horizon for a distinct subgroup. @uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social

📢 Just in: Multivitamins after MI in diabetes? 🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes. 🎯 35% event rate in both arms HR: 0.99 No benefit. #Cardiology #Diabetes #RCT #JAMA

Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/science/yuks... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer

New era for HER2-mutant lung cancer! Zongertinib delivered a 71% response rate, 12.4 months median PFS! No ILD reported. Precision hitting its mark! #LungCancer #Oncology #Targeted #cancerresearch @nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social

Abstracts are out for #ASCO25! 5000+ studies. 5 Plenary game-changers. @ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

The ESMO Research Fellowship is now open. A chance to dive deep into science, grow globally, and shape the future of cancer care. Ready to make impact? @myesmo.bsky.social @oncoalert.bsky.social @ptarantinomd.bsky.social @antoniopassaro.bsky.social @drchoueiri.bsky.social

Many kudos to @ascocancer.bsky.social amazing #SoMe staff for putting together this great highlight of #ASCO25 planning. Getting a moment to hang with the real stars 🤩 inc @ryannipp.bsky.social and my #MedEd colleagues. Looking forward to May in Chicago 🌃

Thrilled to announce that our article has been selected as a Top Viewed Article in Cancer journal! “Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents” Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social

Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊

What if we screened smarter, not just more? In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy— 40% had prostate cancer. Over half needed treatment. Most would’ve been missed by PSA alone. Genetics is rewriting the rules. @nejm.org @myesmo.bsky.social @oncoalert.bsky.social

🧬 Genomic testing in childhood & young adult cancers: 🧬16–18% carry germline variants 🧬Somatic findings guide Dx in up to 95% 🧬Matched therapy? Often possible—rarely given The science is ready. Let’s make care catch up. @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social

🧬 Bigger isn’t always better— In this randomized trial, a large 324-gene panel (F1CDX) identified more matched therapies vs. a smaller panel (51.6% vs 36.9%, +14.8%) But… no survival benefit seen. More targets ≠ better outcomes—yet. @oncoalert.bsky.social @viveksubbiah.bsky.social rdcu.be/egWk9

I’m always inspired by the brilliant minds on this list (and many others!) who generously share insights and push the field of oncology forward. Grateful to @larvol for the inclusion. @ascocancer.bsky.social

Can a shingles vaccine protect the brain? Zoster vaccination linked to a 20% lower risk of dementia over 7 years. @nature.com rdcu.be/egydp

TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers—where immunotherapy usually fails. Neoantigen recognition may be the key. @oncoalert.bsky.social @nature.com @viveksubbiah.bsky.social @jameabraham.bsky.social